NSCLC, Non-small-cell Lung Carcinoma
Conditions
Brief summary
Durvalumab was approved in the Russian Federation for use after both concurrent and subsequent CRT until disease progression. Currently, there is no real-world data regarding the safety and real world effectiveness of durvalumab in this indication. Moreover, generation data on the safety and real world effectiveness of durvalumab after concurrent chemo-radiation therapy (cCRT) and subsequent chemo-radiation therapy (sCRT) in routine practice in the Russian Federation will be of high relevance. The other important question that needs to be addressed is the duration of treatment with durvalumab and its' influence on the relevant outcomes. According to the Russian label, it is possible to continue treatment with durvalumab until disease progression, although current data from the PACIFIC trial provide the results on 12 months duration of durvalumab treatment. The real-world data about the duration of treatment with durvalumab in the Russian population and its' influence on various outcomes would be very important. Among other goals, the current study is aimed to analyze factors influencing the effectiveness of durvalumab therapy in the real-world setting (e.g. duration of treatment, delays in the start of treatment with durvalumab after CRT over, early discontinuation due to any factors including AEs, etc.). The study also aims to elucidate treatment approaches after discontinuation from durvalumab (post-progression outcomes and treatment in case of discontinuation due to AEs). This study will support the understanding of described factors and will take and an attempt to optimize the treatment process to improve outcomes for patients
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients are eligible to be included in the study only if all of the following inclusion criteria and none of the
Exclusion criteria
apply: * Written informed consent obtained from the patient prior to performing any protocol-related procedures * Age ≥18 years at time of study entry * Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent, unresectable (stage III) disease (according to American Joint Committee on Cancer \[AJCC\] lung cancer edition 8) * Patients must have completed a platinum-based chemotherapy with radiation therapy (concurrent or sequential) without evidence of disease progression * Patients must have been treated with at least one dose of durvalumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of durvalumab in patients with unresectable locally advanced NSCLC without progression after CRT in routine practice of the Russian Federation. | Up to 54 month |
| Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation. | Up to 54 month |
| Number of any treatment (durvalumab) related AEs by physician diagnosis within all treatment period plus 3 months after durvalumab discontinuation separately for fix dose (1500mg every 4 weeks) and 10mg/kg every 2 weeks dosage. | Up to 54 month |
| Number of irAEs | Up to 54 month |
| Number of SAEs | Up to 54 month |
| Number of grade 3-4 AEs | Up to 54 month |
| Number of post discontinuation irAEs | Up to 54 month |
| Number of AESIs | Up to 54 month |
| Number of AEs which lead to discontinuation | Up to 54 month |
| Time to pneumonitis [median, months] | Up to 54 month |
| Distribution of pneumonitis grades | Up to 54 month |
| Nature of pneumonitis by physician diagnosis [radiation or immune-related] | Up to 54 month |
| Duration of pneumonitis [median, months] | Up to 54 month |
Countries
Russia
Outcome results
None listed